Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Free Cash Flow (2017 - 2025)

Protagonist Therapeutics' Free Cash Flow history spans 9 years, with the latest figure at -$38.6 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 36.83% year-over-year to -$38.6 million; the TTM value through Dec 2025 reached $56.1 million, down 69.54%, while the annual FY2025 figure was $56.1 million, 69.54% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$38.6 million at Protagonist Therapeutics, down from -$587000.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $268.6 million in Q2 2024 and bottomed at -$38.6 million in Q4 2025.
  • The 5-year median for Free Cash Flow is -$27.8 million (2021), against an average of -$2.4 million.
  • The largest YoY upside for Free Cash Flow was 1117.04% in 2024 against a maximum downside of 272.31% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$28.0 million in 2021, then decreased by 13.17% to -$31.7 million in 2022, then soared by 151.58% to $16.4 million in 2023, then crashed by 272.31% to -$28.2 million in 2024, then crashed by 36.83% to -$38.6 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Free Cash Flow are -$38.6 million (Q4 2025), -$587000.0 (Q3 2025), and -$30.1 million (Q2 2025).